Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05518500
Other study ID # 22-179J-1
Secondary ID U01AI165452
Status Recruiting
Phase Phase 4
First received
Last updated
Start date August 31, 2022
Est. completion date December 31, 2026

Study information

Verified date September 2022
Source The Jackson Laboratory
Contact Lisa Kenyon-Pesce, MPH
Phone 860-679-2305
Email kenyon-pesce@uchc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, single-arm study designed to understand the mechanisms that lead to a loss of response to influenza vaccine in older adults. The investigators will recruit and longitudinally follow a cohort of 66 older adults (65 years and older) who will receive three different influenza vaccines over three annual influenza seasons. Blood samples will be collected from the participants at each of the sixteen study visits over three years. Nasal swab and stool samples will also be collected from participants at seven time-points across the study period. The study is not designed to assess safety or tolerability of the influenza vaccines administered as part of this study.


Description:

This prospective, single-arm study is designed to understand the mechanisms that lead to a loss of response to influenza vaccine in older adults through the establishment of the FluVax3 cohort of healthy older adults. In this study, the investigators will perform comprehensive profiling of blood antibodies and immune cells over time, and associate specific age-related immune alterations with vaccine responder or non-responder status. This will allow the investigators to pinpoint biological pathways that can be targeted to enhance vaccine efficacy and that can also help the investigators progress towards developing a universal influenza vaccine. The results are expected to provide the foundation for new approaches to improve overall vaccine efficacy and protection in older adults, an outcome of significant public health relevance considering the vulnerability of this population. In this study, a total of sixty-six (66) healthy adults aged 65 years and older who have not received influenza vaccination for the approaching influenza season will be enrolled in the study and vaccinated with influenza vaccines approved by the U.S Food and Drug Administration (FDA) and recommended by the Centers for Disease Control and Prevention (CDC) for individuals ≥65 years. All participants receive influenza vaccine during the 2022-23, 2023-24, and 2024-25 influenza seasons. Participants will receive Fluzone® Quadrivalent High-Dose vaccine during the 2022-23 flu season and FLUAD® Quadrivalent during the 2023-24 flu season. The researchers of this proposed study will reevaluate the CDC recommendations and vaccine availability for the 2024-25 season to determine the third vaccine. The study sample will be drawn from the population of healthy older participants in the catchment area of UConn Health in Farmington, CT. Study participation will involve six study visits around the flu vaccine each year and one final study visit for a total of nineteen study visits over three years. Blood samples will be collected at sixteen study visits for transcriptional, epigenetic and biological analyses pre- and post-vaccination. Nasal swab and stool samples will also be collected from participants at seven time-points across the study period. These microbiome samples will be stored and used in future research. The study is not designed to assess safety or tolerability of the influenza vaccines administered as part of this proposed study. This project will yield an unparalleled dataset from healthy older adults that will be used to identify fundamental mechanisms, cell populations, and pathways associated with durable protective antibody immune responses, and lack thereof, upon influenza vaccination. In sum, this study will reveal the mechanistic alterations that explain the heterogeneity in response to vaccines observed in older individuals. Understanding this heterogeneity opens the possibility of stratifying older adults for personalized vaccines. In addition, understanding the mechanistic overlap between the correlates of responsiveness to three different influenza vaccines will advance the ultimate development of a universal influenza vaccine, which is a key focus of NIAID's influenza research program. Finally, this study will generate a considerable amount of transcriptional and functional data related to the outputs of key innate immune and T/B-cell subsets involved in responses to influenza vaccines in older adults. These data will collectively become an important resource for future studies focused on the older adult immune system in health and disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 66
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Able to speak and read English - Male or Female, 65 years and older by September 1, 2022 - Weight of 110 lbs or greater - Has received influenza vaccine in the past seasons without severe adverse reactions - Willing to receive an FDA-approved age-appropriate and CDC-recommended influenza vaccine for each of the 2022-23, 2023-24, and 2024-25 influenza seasons - Willing to withhold all other vaccinations 2 weeks prior and 2 weeks after flu vaccination for the 2022-23, 2023-24, and 2024-25 influenza seasons - Willing and available to participate in 19 study visits over three years around influenza vaccination - Willing to provide blood samples at sixteen visits over three years - Willing to agree to genomic testing of samples and sharing of de-identified genomic data generated from samples at the conclusion of the research Exclusion Criteria: - Received any vaccine (shingles, pneumococcal, COVID, etc.) within 2 weeks of anticipated flu vaccination for the 2022-23, 2023-24, and 2024-25 influenza seasons. - Has already received an influenza vaccine for the approaching influenza season (2022-23) - Has allergy to eggs or any component of the flu vaccine. [Although the Advisory Committee on Immunization Practices (ACIP) has concluded that a history of anaphylactic/anaphylactoid or severe allergic reaction to eggs should no longer be considered a contraindication to vaccination with any age-appropriate vaccine, for the purposes of this research study we elected to exclude individuals with these allergies] - History of Guillain-Barre syndrome (GBS) occurring within 6 weeks following previous influenza vaccination. - Body temperature greater than 100.3°F (38°C) on date of vaccination or within 2 days prior to vaccination by participant report (study entry may be delayed to meet this requirement) - Rockwood Frailty Index score of >0.21 - Known history of any of the following co-morbid conditions: - Chronic or recent (within past 2 months) infection requiring oral or intravenous antibiotics, antifungals, or antivirals - Cancer other than basal cell carcinoma requiring active surgical or medical treatment (chemotherapy or radiation therapy) - Congestive Heart Failure - Ischemic Heart Disease - Congenital abnormalities (PI to evaluate) - Paget's disease - Renal failure requiring ongoing dialysis - Chronic obstructive pulmonary disease, emphysema, or asthma - Severe autoimmune disease requiring biological therapy - Diabetes mellitus requiring insulin - Use of medicines during past 6 months known to alter immune response such as high-dose corticosteroids (= 10 mg/day of prednisone or equivalent) - HIV, AIDS or other immunodeficiency disorders - Recent (= 3 months) severe trauma or major surgery (PI to evaluate) - Current substance and/or alcohol abuse - Patients currently residing in the Department of Correction - Inability to comply with the protocol requirements - Any other condition that, in the opinion of the PI, might interfere with study objectives

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Flu Vaccine (Year 1)
Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.
Flu Vaccine (Year 2)
Participants will receive FLUAD® Quadrivalent in the 2023-2024 flu season.
Flu Vaccine (Year 3)
The flu vaccine to be administered in the 2024-2025 flu season is to be determined. Researchers are hoping that by the 2024-2025 flu season an mRNA-based influenza vaccine will be approved by the FDA and available for use in this study. In the event an mRNA vaccine is not available, researchers will reassess the vaccine to be administered in Year 3.

Locations

Country Name City State
United States UConn Health, Center On Aging Farmington Connecticut

Sponsors (6)

Lead Sponsor Collaborator
The Jackson Laboratory Icahn School of Medicine at Mount Sinai, National Institute of Allergy and Infectious Diseases (NIAID), UConn Health, University of Chicago, Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Antibody Responses to Influenza Vaccine Year One In year one, healthy older participants will receive Fluzone Quadrivalent HD vaccine. Longitudinal blood samples will be collected and influenza-specific antibody responses will be assessed. Change in antibody response will be measured using Hemagglutination Inhibition (HAI) from baseline to day 35 and day 180. Baseline, Day 35, Day 180
Primary Change in Antibody Responses to Influenza Vaccine Year Two In year two, healthy older participants will receive FLUAD vaccine. Longitudinal blood samples will be collected and influenza-specific antibody responses will be assessed. Change in antibody response will be measured using Hemagglutination Inhibition (HAI) from baseline to day 35 and day 180. Baseline, Day 35, Day 180
Primary Change in Antibody Responses to Influenza Vaccine Year Three In year three, healthy older participants will receive a CDC recommended FDA approved influenza vaccine. Longitudinal blood samples will be collected and influenza-specific antibody responses will be assessed. Change in antibody response will be measured using Hemagglutination Inhibition (HAI) from baseline to day 35 and day 180. Baseline, Day 35, Day 180
Secondary Evaluate changes in functional status of immune cells in response to Influenza Vaccine in Year One Evaluate changes in functional status of immune cells in older participants following administration of Fluzone Quadrivalent HD vaccine. A longitudinal analysis of different cell populations (B Cells, Functional T/B Cells, and monoclonal antibodies) in whole blood samples will be analyzed at baseline and 35 days post vaccination using single cell assays and ELISA. Baseline, Day 7, Day 35
Secondary Evaluate changes in functional status of immune cells in response to Influenza Vaccine in Year Two Evaluate changes in functional status of immune cells in older participants following administration of FLUAD vaccine. A longitudinal analysis of different cell populations (B Cells, Functional T/B Cells, and monoclonal antibodies) in whole blood samples will be analyzed at baseline and 35 days post vaccination using single cell assays and ELISA. Baseline, Day 7, Day 35
Secondary Evaluate changes in functional status of immune cells in response to Influenza Vaccine in Year Three Evaluate changes in functional status of immune cells in older participants following administration of CDC recommended FDA approved influenza vaccine. A longitudinal analysis of different cell populations (B Cells, Functional T/B Cells, and monoclonal antibodies) in whole blood samples will be analyzed at baseline and 35 days post vaccination using single cell assays and ELISA. Baseline, Day 7, Day 35
Secondary Number of genes upregulated in response to Influenza Vaccine in Year One RNA-seq and scRNA-seq will be used to assess the number of genes upregulated in response to Fluzone Quadrivalent HD vaccination. Baseline, Day1, Day 7
Secondary Number of genes upregulated in response to Influenza Vaccine in Year Two RNA-seq and scRNA-seq will be used to assess the number of genes upregulated in response to FLUAD vaccination. Baseline, Day 1, Day 7
Secondary Number of genes upregulated in response to Influenza Vaccine in Year Three RNA-seq and scRNA-seq will be used to assess the number of genes upregulated in response to CDC recommended FDA approved influenza vaccination. Baseline, Day1, Day 7
Secondary Number of chromatin accessibility regions activated in response to Influenza Vaccine in Year One snATAC-seq will be used to assess the number of open chromatin regions activated in response to Fluzone Quadrivalent HD vaccination. Baseline, Day1, Day 7
Secondary Number of chromatin accessibility regions activated in response to Influenza Vaccine in Year Two snATAC-seq will be used to assess the number of open chromatin regions activated in response to FLUAD vaccination. Baseline, Day1, Day 7
Secondary Number of chromatin accessibility regions activated in response to Influenza Vaccine in Year Three snATAC-seq will be used to assess the number of open chromatin regions activated in response to CDC recommended FDA approved influenza vaccination. Baseline, Day1, Day 7
Secondary Changes in number of cDCs, Tfh, Th10, and B lymphocytes in response to Influenza Vaccine in Year One Flow cytometry will be used to assess cell compositional changes in PBMCs and immune cell subsets (cDCs, Tfh, Th10, and B lymphocytes) in response to Fluzone Quadrivalent HD vaccination. Baseline, Day1, Day 7, Day 35, Day 180
Secondary Changes in number of cDCs, Tfh, Th10, and B lymphocytes in response to Influenza Vaccine in Year Two Flow cytometry will be used to assess cell compositional changes in PBMCs and immune cell subsets (cDCs, Tfh, Th10, and B lymphocytes) in response to FLUAD vaccination. Baseline, Day1, Day 7, Day 35, Day 180
Secondary Changes in number of cDCs, Tfh, Th10, and B lymphocytes in response to Influenza Vaccine in Year Three Flow cytometry will be used to assess cell compositional changes in PBMCs and immune cell subsets (cDCs, Tfh, Th10, and B lymphocytes) in response to CDC recommended FDA approved influenza vaccination. Baseline, Day1, Day 7, Day 35, Day 180
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A